-+ 0.00%
-+ 0.00%
-+ 0.00%

Abivax Presents Third Quarter 2025 Financial Results

Barchart·12/15/2025 15:08:00
Listen to the news

Abivax Presents Third Quarter 2025 Financial Results

PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial information for the nine months ended September 30, 2025. The unaudited interim condensed consolidated financial statements as of and for the three and nine months ending September 30, 2025, reviewed by the Company’s Board of Directors on December 11, 2025, have been reviewed by the Company’s external auditors.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.